Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
January 13 2020 - 7:30AM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that its Chief Executive Officer and President,
Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan
Healthcare Conference at 12:00 p.m. PST on Wednesday, January 15,
2020. Mr. Auerbach will be providing a corporate update that will
include, among other things, the company’s preliminary estimate
that it sold approximately 4,900 bottles of NERLYNX in the United
States in the fourth quarter of 2019. This preliminary estimate is
subject to completion of the Company’s customary closing and review
procedures and could change based on that process. The slides to be
discussed during the presentation are currently available on the
Investors section of Puma’s website at
https://investor.pumabiotechnology.com/sec-filings/all-filings/default.aspx.
A live webcast of the presentation will also be available on
January 15, 2020, at www.pumabiotechnology.com.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. Puma in-licenses the global
development and commercialization rights to PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral
was approved by the U.S. Food and Drug Administration in July 2017
for the extended adjuvant treatment of adult patients with early
stage HER2-overexpressed/amplified breast cancer, following
adjuvant trastuzumab-based therapy and is marketed in the United
States as NERLYNX® (neratinib) tablets. NERLYNX was granted
marketing authorization by the European Commission in August 2018
for the extended adjuvant treatment of adult patients with early
stage hormone receptor-positive HER2-overexpressed/amplified breast
cancer and who are less than one year from completion of prior
adjuvant trastuzumab-based therapy. NERLYNX is a registered
trademark of Puma Biotechnology, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200113005125/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.,
+1 424 248 6500 info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Apr 2023 to Apr 2024